Segmented Information
 12 Months Ended
Nov. 30, 2021
Segmented Information  
Segmented Information

18. Segmented information

 

The Company's operations comprise a single reportable segment engaged in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. As the operations comprise a single reportable segment, amounts disclosed in the financial statements for revenue, loss for the period, depreciation and total assets also represent segmented amounts. In addition, allof the Company's long-lived assets are in Canada. The Company’s license and commercialization agreement with Par accounts for substantially all of the revenue of the Company.

 

 

 

November 30,

 

 

November 30,

 

 

November 30,

 

 

 

2021

 

 

2020

 

 

2019

 

 

 

$

 

 

$

 

 

$

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

United States

 

 

-

 

 

 

1,401,517

 

 

 

3,480,516

 

 

 

 

-

 

 

 

1,401,517

 

 

 

3,480,516

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total assets

 

 

 

 

 

 

 

 

 

 

 

 

Canada

 

 

2,096,425

 

 

 

3,387,055

 

 

 

3,796,713

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total property and equipment

 

 

 

 

 

 

 

 

 

 

 

 

Canada

 

 

994,109

 

 

 

1,770,137

 

 

 

2,273,406

 

19. Subsequent event

 

On December 1, 2021, the Company extended its lease for the premises (30 Worcester Road) that it currently operates from, for one year, commencing December 1, 2021, with lease expiring on December 31, 2022 with an option to renew for another year.